Monday, December 13, 2010

HRT Increases risk of TNBC

Combined hormonal replacement therapy—using estrogen plus progestin—is associated with a 78 percent increase in triple-negative cancers, a twofold increase in HER2-positive tumors, and a 37 percent increase in HER2-negative tumors, according to Women’s Health Initiative results presented at the San Antonia Breast Cancer Symposium. And it nearly doubles the risk of death from breast cancer. In the past, HRT was associated strongly with hormone-positive cancers, but not hormone-negative.

Data were from WHI randomized trials after 11 years of follow-up.

Read the entire story from Internal Medicine News.


No comments: